acalabrutinib

Abdullah S Shaikh1, Susan C Abraham2, Lan S Wang1

  • 1Department of Gastroenterology, Hepatology, and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX.

PubMed
概括

乙型肝炎病毒 (HBVr) 再激活是免疫抑制剂的风险. 这一案例突出了在接受了布鲁顿氨酸激酶抑制剂acalabrutinib治疗的患者的HBVr,用于地幔细胞淋巴瘤.